Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study

J Eur Acad Dermatol Venereol. 2024 Feb;38(2):e152-e154. doi: 10.1111/jdv.19507. Epub 2023 Sep 20.

Authors

L Gargiulo^{1

2}, L Ibba^{1

2}, F Piscazzi^{1

2}, A Alfano^{1

2}, R Cascio Ingurgio^{1

2}, M Valenti^{1

2}, A Costanzo^{1

2}, A Narcisi¹

Affiliations

¹ Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.

PMID: 37714196
DOI: 10.1111/jdv.19507

No abstract available

Publication types

Letter

MeSH terms

Dermatitis, Atopic* / drug therapy
Double-Blind Method
Heterocyclic Compounds, 3-Ring
Humans
Retrospective Studies
Severity of Illness Index
Treatment Outcome

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring